Another Milestone! Trulive's TruGamma® Transcatheter Tricuspid Valve Replacement System Granted NMPA Special Review for Innovative Medical Devices

TruGamma® Transcatheter Tricuspid Valve Replacement System, independently developed by Jiangsu Trulive Medtech Co., Ltd. ("Trulive Medical"), has officially passed the Special Review for Innovative Medical Devices administered by the National Medical Products Administration (NMPA).

TruGamma® Transcatheter Tricuspid Valve Replacement System, independently developed by Jiangsu Trulive Medtech Co., Ltd. ("Trulive Medical"), has officially passed the Special Review for Innovative Medical Devices administered by the National Medical Products Administration (NMPA).

Related Articles

You might also be interested in these

Trulive Completes New Round of Over 100 Million Yuan Series C Financing, Continuing to Strengthen Platform Layout in Cardiovascular Intervention

Trulive Completes New Round of Over 100 Million Yuan Series C Financing, Continuing to Strengthen Platform Layout in Cardiovascular Intervention

10/10/2026

Trulive Medical Launches NeoBlazar® Transcatheter Edge-to-Edge Repair System, Marking the New Domestic Era for Tricuspid Interventional Therapy

Trulive Medical Launches NeoBlazar® Transcatheter Edge-to-Edge Repair System, Marking the New Domestic Era for Tricuspid Interventional Therapy

7/22/2026

Double List Honors! Trulive Medical Named to Future Healthcare 100 List Again, Dual Rankings Demonstrate Solid Innovation Capabilities

Double List Honors! Trulive Medical Named to Future Healthcare 100 List Again, Dual Rankings Demonstrate Solid Innovation Capabilities

5/22/2026